semaglutide sales Market Size & Share, Growth Analysis 2035 India Weight-Loss Drug Sales Slow

Tirzepatide, having received FDA approval, has a more defined safety record, though patients should be monitored for potential risks such as pancreatitis or thyroid tumors, which have been concerns with GLP-1 receptor agonists in general

GLP-1s are powerful drugs

These are estimates based on group means

In addition, symptoms are evaluated, including: Muscle weakness Loss of stamina during activity Difficulty performing daily activities Walking slowly Difficulty climbing stairs Balance issues Increased incidence of falls Shrinking muscles Muscle loss is a risk of weight loss Maintaining muscle while losing fat is critical to the success of weight loss efforts